Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Ronen Arbel

Showing results (11-20 of 60) with videos related to

Pageof 6
Sort By:
Ejhaem|July 3, 2026
Vitamin D Supplementation and Treatment-Free Survival in Early-Stage CLL: A Real-World Validation StudyTamar Tadmor, Ronen Arbel, Talish Razi, et al.
American Journal of Cardiovascular Drugs : Drugs, Devices, and Other Interventions|October 21, 2021
Dapagliflozin Versus Sacubitril-Valsartan to Improve Outcomes of Patients with Reduced Ejection Fraction and Diabetes MellitusAriel Hammerman, Joseph Azuri, Enis Aboalhasan, et al.
International Journal of Cardiology|July 9, 2016
PCSK9 inhibitors may improve cardiovascular outcomes-Can we afford them?Ronen Arbel, Ariel Hammerman, Noa Triki, et al.
Clinical Drug Investigation|May 26, 2020
Sodium-Glucose Cotransporter 2 Inhibitors for Prevention of Heart Failure Events in Patients with Type 2 Diabetes Mellitus: A Cost Per Outcome AnalysisRonen Arbel, Enis Aboalhasan, Ariel Hammerman, et al.
European Journal of Preventive Cardiology|February 24, 2021
Dapagliflozin vs. sacubitril-valsartan for prevention of heart failure events in non-diabetic patients with reduced ejection fraction: a cost per outcome analysisRonen Arbel, Enis Aboalhasan, Ariel Hammerman, et al.
Childhood Obesity (Print)|October 6, 2025
Adherence and Effectiveness of Liraglutide in Adolescents with ObesityShlomit Yaron, Ronen Arbel, Talish Razi, et al.
American Journal of Infection Control|December 31, 2021
How many lives do COVID vaccines save? Evidence from IsraelRonen Arbel, Candace Makeda Moore, Ruslan Sergienko, et al.
Obesity (Silver Spring, Md.)|May 19, 2023
Liraglutide versus semaglutide for weight reduction-a cost needed to treat analysisJoseph Azuri, Ariel Hammerman, Enis Aboalhasan, et al.
Diabetes, Obesity & Metabolism|December 12, 2022
Tirzepatide versus semaglutide for weight loss in patients with type 2 diabetes mellitus: A value for money analysisJoseph Azuri, Ariel Hammerman, Enis Aboalhasan, et al.
Journal of Child and Adolescent Psychopharmacology|December 3, 2025
Medical Cannabis Use in Autism: Insights from an Israeli HMO on Patient Characteristics and Alignment with National GuidelinesHadar Sadeh, Talish Razi, Ronen Arbel, et al.
Pageof 6

Showing results (11-20 of 60) with videos related to

Sort By:
Pageof 6
Ejhaem|July 3, 2026
Vitamin D Supplementation and Treatment-Free Survival in Early-Stage CLL: A Real-World Validation StudyTamar Tadmor, Ronen Arbel, Talish Razi, et al.
American Journal of Cardiovascular Drugs : Drugs, Devices, and Other Interventions|October 21, 2021
Dapagliflozin Versus Sacubitril-Valsartan to Improve Outcomes of Patients with Reduced Ejection Fraction and Diabetes MellitusAriel Hammerman, Joseph Azuri, Enis Aboalhasan, et al.
International Journal of Cardiology|July 9, 2016
PCSK9 inhibitors may improve cardiovascular outcomes-Can we afford them?Ronen Arbel, Ariel Hammerman, Noa Triki, et al.
Clinical Drug Investigation|May 26, 2020
Sodium-Glucose Cotransporter 2 Inhibitors for Prevention of Heart Failure Events in Patients with Type 2 Diabetes Mellitus: A Cost Per Outcome AnalysisRonen Arbel, Enis Aboalhasan, Ariel Hammerman, et al.
European Journal of Preventive Cardiology|February 24, 2021
Dapagliflozin vs. sacubitril-valsartan for prevention of heart failure events in non-diabetic patients with reduced ejection fraction: a cost per outcome analysisRonen Arbel, Enis Aboalhasan, Ariel Hammerman, et al.
Childhood Obesity (Print)|October 6, 2025
Adherence and Effectiveness of Liraglutide in Adolescents with ObesityShlomit Yaron, Ronen Arbel, Talish Razi, et al.
American Journal of Infection Control|December 31, 2021
How many lives do COVID vaccines save? Evidence from IsraelRonen Arbel, Candace Makeda Moore, Ruslan Sergienko, et al.
Obesity (Silver Spring, Md.)|May 19, 2023
Liraglutide versus semaglutide for weight reduction-a cost needed to treat analysisJoseph Azuri, Ariel Hammerman, Enis Aboalhasan, et al.
Diabetes, Obesity & Metabolism|December 12, 2022
Tirzepatide versus semaglutide for weight loss in patients with type 2 diabetes mellitus: A value for money analysisJoseph Azuri, Ariel Hammerman, Enis Aboalhasan, et al.
Journal of Child and Adolescent Psychopharmacology|December 3, 2025
Medical Cannabis Use in Autism: Insights from an Israeli HMO on Patient Characteristics and Alignment with National GuidelinesHadar Sadeh, Talish Razi, Ronen Arbel, et al.
Pageof 6